Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting of HIV drug resistance (HIVDR) prevalence or incidence studies. |
| Full bibliographic reference | Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin A, Mor O, Parkin N, Santoro MM, Ávila-Ríos S, Fokam J, Phillips A, Shafer RW, Jordan MR. Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use. Lancet HIV. 2023:S2352-3018(23)00173-X. |
| Language | English |
| PubMed ID | 37716367 |
| Relevant URLs (full-text if available) |
The checklists are available from the CEDRIC-HIV website. |
| Availability in additional languages | Translations of the checklist are avilable in French, Portuguese, Chinese, Spanish and Italian. |
| Reporting guideline website URL | http://cedric-hiv.com/ |
| Reporting guideline acronym | CEDRIC-HIV |
| Study design | Clinical trials, Experimental studies, Observational studies |
| Clinical area | Infectious diseases, Public health |
| Applies to the whole report or to individual sections of the report? | Whole report |
| Record last updated on | September 28, 2023 |